Indian Drug Makers Increase Nutraceutical Activity
This article was originally published in PharmAsia News
Executive SummarySeveral Indian drug makers are expanding their nutraceutical products to take advantage of an expected explosion in the market. The pharmaceutical industry estimates the nutraceutical segment of medicine to be worth about $400 million in India, a major part of a $7 billion health care sector. An Ernst & Young partner questioned, however, whether the segment also should include ayurvedic and herbal products, which in India are considered drugs for regulatory purposes. Those products are expected to reach $190 billion in sales by 2010. Among drug makers seeking to expand are Elder Pharma, Glenmark, Plethico, Troikaa and Wockhardt. (Click here for more
You may also be interested in...
A new coronavirus test template developed by the US Centers for Disease Control and Prevention is being refined by the agency so it can be shared with domestic and international partners to help identify more cases of the virus. In the meantime, state labs can use the posted assay for coronavirus on the CDC’s website for testing of residents within their jurisdiction and send results to the CDC.
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
Dr Reddy’s Laboratories reported an unexpected third-quarter consolidated net loss after taking a $156m charge related to its generic version of the NuvaRing contraceptive. However, the company’s shares jumped on a robust underlying performance that was praised by analysts.